Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Valuation & Earnings
This table compares Northwest Biotherapeutics and Gossamer Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Northwest Biotherapeutics | $1.93 million | 202.16 | -$62.60 million | ($0.07) | -4.53 |
| Gossamer Bio | $95.84 million | 2.48 | -$179.82 million | ($1.06) | -0.99 |
Northwest Biotherapeutics has higher earnings, but lower revenue than Gossamer Bio. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Northwest Biotherapeutics | -4,479.03% | N/A | -253.74% |
| Gossamer Bio | N/A | -117.33% | -25.02% |
Risk and Volatility
Northwest Biotherapeutics has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
Insider & Institutional Ownership
0.0% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 8.7% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 5.0% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Northwest Biotherapeutics and Gossamer Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Northwest Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
| Gossamer Bio | 0 | 0 | 5 | 0 | 3.00 |
Gossamer Bio has a consensus target price of $9.20, suggesting a potential upside of 776.19%. Given Gossamer Bio’s higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Northwest Biotherapeutics.
Summary
Gossamer Bio beats Northwest Biotherapeutics on 8 of the 13 factors compared between the two stocks.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
